Abstract:Lung cancer is one of the most common malignant tumors and has a poor prognosis and a low survival rate. Traditional treatments, such as radiotherapy and chemotherapy, still face some challenges because of high drug resistance and toxicity. Therefore, it is necessary to discover a new kind of targeted drug with low toxicity and high efficiency. CDK12 is a cell cycle-dependent kinase whose main function is to activate RNA polymerase II (RNAPII) and promote the transcriptional extension of RNA. However, the role and molecular mechanism of CDK12 in lung cancer are still unclear. In this study, the mutation and RNA-Seq data of CDK12 in lung adenocarcinoma and squamous cell carcinoma were downloaded from The Cancer Genome Atlas (TCGA) database and analyzed with the custom scripts. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) and cell colony formation assays. A subcutaneous tumor experiment in nude mice was used to examine the effects of CDK12 knockdown on the in vivo tumor growth of NSCLC cells. The cell cycle distribution and the apoptosis rate of lung cancer cells were assessed by flow cytometry. Regulation of TANK-binding kinase 1 (TBK1) by CDK12 was evaluated by quantitative PCR, immunoprecipitation and Western blot analysis. In this study we have analyzed the mutation and expression data of The Cancer Genome Atlas (TCGA) database and found that CDK12 is highly expressed in lung cancer tissues. Clinical correlation analysis showed that high expression of CDK12 in NSCLC reduces patient survival, but its high expression is only related to early tumor progression and has no significant correlation with late tumor progression and metastasis. Furthermore, we present evidence that CDK12 depletion in lung cancer cell lines not only leads to the inhibition of cell growth and induces apoptosis but also inhibits tumor growth of NSCLC cells in vivo. CDK12 positively regulates the expression of the oncogene TBK1 in lung cancer cells. These results revealed that CDK12 affects the progression of non-small cell lung cancer through positive regulation of TBK1 expression, suggesting that CDK12 might be a potential molecular target for the treatment of non-small cell lung cancer.

CDK12 is a Promising Therapeutic Target for the Transcription Cycle and DNA Damage Response in Metastatic Osteosarcoma.

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Cyclin-Dependent Kinase 7 (Cdk7) Is An Emerging Prognostic Biomarker And Therapeutic Target In Osteosarcoma

Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Promotion of Proliferation and Inhibition of Apoptosis by Diacylglycerol Kinase Zeta, a Potential Oncogene of Osteosarcoma

Comprehensive analysis of the expression and prognosis for cyclin-dependent protein kinase family in osteosarcoma

Mir-216A Inhibits Osteosarcoma Cell Proliferation, Invasion and Metastasis by Targeting CDK14.

Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.

Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition.

Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation

Abstract #3119: Transcriptional Profiling Identifies the Signaling Axes of the Insulin-Like Growth Factor and the Transforming Growth Factor-\#946; in the Pathogenesis of Osteosarcoma

DGKZ Acts As a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction with ERK1/2 and MYC Pathway

CDKL3 Promotes Osteosarcoma Progression by Activating Akt/PKB

Selected Using Bioinformatics and Molecular Docking Analyses, PHA-793887 is Effective Against Osteosarcoma

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells

CDH4 is a Novel Determinant of Osteosarcoma Tumorigenesis and Metastasis

Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.